These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29927948)

  • 1. The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy.
    Barcelona PF; Galan A; Nedev H; Jian Y; Sarunic MV; Saragovi HU
    PLoS One; 2018; 13(6):e0199079. PubMed ID: 29927948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p75NTR and Its Ligand ProNGF Activate Paracrine Mechanisms Etiological to the Vascular, Inflammatory, and Neurodegenerative Pathologies of Diabetic Retinopathy.
    Barcelona PF; Sitaras N; Galan A; Esquiva G; Jmaeff S; Jian Y; Sarunic MV; Cuenca N; Sapieha P; Saragovi HU
    J Neurosci; 2016 Aug; 36(34):8826-41. PubMed ID: 27559166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.
    Galan A; Barcelona PF; Nedev H; Sarunic MV; Jian Y; Saragovi HU
    Invest Ophthalmol Vis Sci; 2017 Jun; 58(7):2852-2862. PubMed ID: 28570737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of placental growth factor as a novel treatment option in diabetic retinopathy.
    Van Bergen T; Hu TT; Etienne I; Reyns GE; Moons L; Feyen JHM
    Exp Eye Res; 2017 Dec; 165():136-150. PubMed ID: 28965804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.
    Dugel PU; Blumenkranz MS; Haller JA; Williams GA; Solley WA; Kleinman DM; Naor J
    Ophthalmology; 2012 Jan; 119(1):124-31. PubMed ID: 22115710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
    Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
    Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
    Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
    Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
    Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema.
    Synek S; Vojniković B
    Coll Antropol; 2010 Apr; 34 Suppl 2():99-103. PubMed ID: 21305729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
    Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
    J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
    Lim JW; Lee HK; Shin MC
    Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
    Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
    Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complications of intravitreal injections--own experience].
    Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
    Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct intracellular selection and biochemical characterization of a recombinant anti-proNGF single chain antibody fragment.
    Paoletti F; Malerba F; Konarev PV; Visintin M; Scardigli R; Fasulo L; Lamba D; Svergun DI; Cattaneo A
    Arch Biochem Biophys; 2012 Jun; 522(1):26-36. PubMed ID: 22516657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.